Bruker has acquired MIMETAS, a Dutch developer of screenable, physiologically relevant 3D human disease models, for an undisclosed amount. The transaction brings the organ-on-a-chip specialist under Bruker’s ownership, expanding the latter’s portfolio beyond its traditional analytical instrumentation base.
MIMETAS focuses on creating organ-on-a-chip platforms that replicate human tissue and disease states in a laboratory setting. Its technology combines microfluidics with 3D cell culture to produce models used by global pharmaceutical companies in drug development partnerships. The company offers services and establishes collaborations aimed at developing therapies for currently untreatable diseases, with its website at www.mimetas.com.
For Bruker, the acquisition adds a biological assay and tissue-modeling capability that complements its existing life science tools. The strategic rationale centers on integrating MIMETAS’ disease models with Bruker’s high-resolution imaging and analysis systems, allowing researchers to observe drug responses in a more human-relevant context. This move positions Bruker to serve the growing demand for preclinical models that better predict clinical outcomes, particularly in oncology and rare disease research.
The combined entity is expected to offer a more complete workflow, from model generation to data readout, for pharmaceutical clients. MIMETAS’ expertise in 3D biology will likely be paired with Bruker’s strengths in mass spectrometry and microscopy, creating a bridge between functional assays and molecular analysis. No financial terms were disclosed, and the deal is subject to customary closing conditions.
Following the close, MIMETAS is set to operate as part of Bruker’s life science division, retaining its core team and Dutch operations. The integration is anticipated to accelerate the adoption of organ-on-a-chip technology in drug discovery, with near-term focus on expanding service offerings to existing pharmaceutical partners.